Skip to main content

Laboratory of Oncology and Experimental Surgery (LOCE)

Description

The Laboratory of Oncology and Experimental Surgery (LOCE) is a laboratory at the Institut Bordet recognised by the ULB Faculty of Medicine. It specialises in research into malignant melanoma and pigment cells in general. It combines fundamental research with preclinical and translational research. The LOCE has a self-contained cell culture unit which has established more than 150 primary lines and cultures of normal and tumour cells (mainly melanomas) and adheres to a rigorous quality control programme. The LOCE shares its cell cultures with some 80 research teams around the world.

Research projects

Project 1

EXPLORATION DE L’EFFET RADIOSENSIBILISATEUR DES MÉDICAMENTS CIBLÉS AINSI QUE LEURS COMBINAISONS UTILISÉS DANS LE MÉLANOME POUR AMÉLIORER LA SENSIBILITÉ DES TUMEURS À LA RADIOTHÉRAPIE.

Project 2

PROFILAGE DU KINOME COMME OUTIL PRÉDICTIF DE L’INIHIBITION DES MAPK DANS LE MÉLANOME ET COMME UNE NOUVELLE APPROCHE POUR ÉTUDIER LES MÉCANISMES DE RÉSISTANCE INTRINSÈQUE ET ACQUISE

Project 3

NOUVELLES ASSOCIATIONS MÉDICAMENTEUSES POUR TRAITER LE MÉLANOME MUQUEUX CKIT MUTÉ.

Project 4

LES PROHIBITINES (PHBS) : NOUVELLES CIBLES THÉRAPEUTIQUES POTENTIELLES DANS LE MÉLANOME.

Project 5

NOUVEAUX MARQUEURS PRONOSTIQUES ET DE PROGRESSION AU NIVEAU DES MÉTASTASES DU MÉLANOME.

The team

Head of Unit
Ghanem E. Ghanem

Researchers
Fabrice Journé
Mohammad Krayem
Ahmad Najem
Renato Morandini

PhD students  
Malak Sabbah

Cell Culture Unit
Isabelle Borsu
Marie-Jeanne Gebski

Laboratory Technicians
Philippe Mersch
Marie-Lydie Pelgrims
Lamine Mihoub
Sebahat Yildirim

Data Manager
Laïla Berdouz

Administrative Assistance
Christiane Meunier
Arlinda Rahmani

 Scientific publications

Survival and treatment outcome of head and neck cancer patients with pulmonary oligometastases.

Authors : Lardinois I, Dequanter D, Lechien JR, Bouland C, Javadian R, Rodriguez A, Loeb I, Journe F, Saussez S
Year : 2021
Journal : Clin Otolaryngol
Volume : 46
Pages : 311-317

Dasatinib stimulates its own mechanism of resistance by activating a CRTC3/MITF/Bcl-2 pathway in melanoma with mutant or amplified c-Kit.

Authors : Sabbah M, Krayem M, Najem A, Sales F, Miller W, Del Rincon S, Awada A, Ghanem GE, Journe F
Year : 2021
Journal : Mol Cancer Res

Inhibiting the MNK1/2-eIF4E axis impairs melanoma phenotype switching and potentiates anti-tumor immune responses.

Authors : Huang F, Goncalves C, Bartish M, Rémy-Sarrazin J, Issa ME, Cordeiro B, Guo Q, Emond A, Attias M, Yang W, Plourde D, Su J, Gimeno MG, Zhan Y, Galán A, Rzymski T, Mazan M, Masiejczyk M, Faber J, Khoury E, Benoit A, Gagnon N, Dankort D, Journe F, Ghanem G, Krawczyk CM, Saragovi HU, Piccirillo CA, Sonenberg N, Topisirovic I, Rudd CE, Miller WH Jr, Del Rincón SV
Year : 2021
Journal : J Clin Invest

RTK Inhibitors in Melanoma: From Bench to Bedside.

Authors : Sabbah M, Najem A, Krayem M, Awada A, Journe F, Ghanem GE
Year : 2021
Journal : Cancers (Basel)
Volume : 13

ACE2 Protein Landscape in the Head and Neck Region: The Conundrum of SARS-CoV-2 Infection.

Authors : Descamps G, Verset L, Trelcat A, Hopkins C, Lechien JR, Journe F, Saussez S
Year : 2020
Journal : Biology (Basel)
Volume : 9